ICONIK Labs allows visualisation, analysis and reporting on laboratory data in real time
ICON plc, (NASDAQ: ICLR) a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, today announced ICONIK Labs, the latest service to leverage its ICONIK technology platform.
ICONIK Labs is an interactive analytics tool that allows Clinical and Medical team members to visualise, analyse and report on large volumes of laboratory data in real time. Using ICONIK Labs’ advanced visualisation capabilities, project teams can interact with data and view trends at any level of detail, including patient, site, study or across an entire program through a series of dynamic filters. ICONIK Labs enhances a study’s quality by instantly identifying sites with an unusual number of lab values outside the normal range and can also improve patient safety by providing Hy’s Law analysis which assists with the detection of subjects at risk of Drug Induced Liver Injury (DILI).
Commenting on the new service, Dr. Steve Cutler, Group President, ICON Clinical Research Services, said: “ICONIK Labs has transformed how study teams review and analyse laboratory data and has enabled a fresh approach to combining lab parameters to review study trends. It enables study teams to quickly uncover actionable insights that support earlier, more informed decision-making and more efficient trial management.”
ICONIK Labs is the latest service to leverage the ICONIK technology platform and follows ICON’s recent announcement of ICONIK Monitoring and ICONIK Patient Safety. ICONIK Monitoring is a new service that improves quality and reduces the costs of clinical development through more effective use of monitoring resources. ICONIK Patient Safety enables real-time analysis of aggregated patient safety data, giving study teams the ability to uncover potential medical issues in real-time.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Arcus’ Quemliclustat Earns Orphan Drug Designation as Phase III Pancreatic Cancer Trial Advances
July 11th 2025The FDA has granted orphan status to Arcus Biosciences’ CD73 inhibitor quemliclustat for metastatic pancreatic cancer, as the global PRISM-1 Phase III trial nears full enrollment following promising survival data from ARC-8.
QWINT-1 Trial: Once-Weekly Efsitora Matches Daily Glargine in Type 2 Diabetes Management
July 10th 2025Results from the Phase III QWINT-1 trial show that Eli Lilly’s once-weekly insulin efsitora is noninferior to once-daily glargine in reducing HbA1c among insulin-naïve adults with type 2 diabetes, offering a simplified fixed-dose regimen with fewer hypoglycemic events and less treatment burden.